WebPhathom is a Frazier-founded company focused on developing novel therapeutics for the treatment of gastrointestinal acid-related disorders. The company has licensed rights from Takeda to develop and commercialize vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in the United States, Canada, and Europe. WebAnalyst Coverage. Phathom Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Phathom Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Phathom Pharmaceuticals, Inc. or its management.
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for
WebThe women and girls of today must continue to carry forward the mission of equity and equality in communities around the globe to better the world and help pave the way for … WebMain Operator +1-(877)-742-8466. New Jersey Corporate Headquarters 100 Campus Drive, Suite 102 Florham Park, NJ 07932 Illinois R&D Headquarters 2150 E. Lake Cook Road, Suite 800 my mother was a computer
Phathom Pharmaceuticals: Bringing Vonoprazan To U.S. And ... - SeekingAlpha
WebJan 3, 2024 · FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ... WebPhathom Pharmaceuticals appears in search results as Phathom Pharmaceuticals Inc, Phathom Pharmaceuticals, Odyssey Pharmaceuticals Inc Pharmaceuticals Inc, Phantom … WebPhathom pipeline: promising late-stage opportunities for unmet GI needs Phathom has development and commercialization rights to vonoprazan in the United States, Europe, and Canada 1 Phase 1 and 2 studies in healing of Erosive Esophagitis, maintenance of Erosive Esophagitis, and H. pylori treatment conducted by Takeda 4 GERD old neighborhood grill fort worth tx